Changing trends in HIV and cancer

New anti-retroviral therapies have changed the natural history of HIV. Oncological disease increases its role against infectious complications. Currently, they are one of the main reasons for death and hospitalization. AIDS-defining cancers (ADCs) are Kaposi's sarcoma, non-Hodgkin lymphoma (NHL) and cervical carcinoma. The other cancers are non-AIDS defining (NADCs). An observational, retrospective study of a cohort of patients (p) with HIV-controlled in an Infectious Diseases unit and / or Medical Oncology for 11 years (2004 -2014) was conducted. ADCs and NADs are included, prognostic variables and epidemiological data were analyzed in relation to HIV and tumoral pathology. Of 780 p HIV, 101 tumors were diagnosed in 91 p (12%). Males 71%. Mean age 46 years. In order of frequency: NHL 21 p (23%), lung carcinoma 13 p (14%), Kaposi's sarcoma 9 p (10%), hepatocellular carcinoma 7p (8%). Second malignancy was targeted in 10 p (11%). Since 2009 diagnosis of NADCs, it has increased 54 p (65%) opposite to ADCs 37 p (40%) (p 0.027). 30 p (33%) have achieved complete response of the oncological pathology, 9p (11%) progression and 52 p (56%) death. 42 p (46.2%) had viral load undetectable tumor diagnosis and 30p (33%) CD4 count> 500 / mm3. Of the 91 p, 48 p (53%) had HCV coinfection, 9p (10%) EBV or HPV and 50 p (54%) HBsAg positive. 57 p (63%) smokers> 20 cigarettes / day, 26 p (29%) habitual consumption alcohol. 40 p (44%) had diagnosed > 10 years with HIV and 20 p (22%) HIV diagnosis was made simultaneously to the tumor. SG from HIV diagnosis to exitus in ADCs was 2 years (CI 0- 6,597) and NADCs was 14 years (CI 12,7 - 15.3) (p 0.007 0.397 HR CI 0.204 to 0.773). Our study confirms the appearence of malignancies earlier than in the general population and a significant increase in males not present in other studies. In relation to previous studies, we targeted the change of trend in the complications of p HIV. NADCs prevalence is progressively higher than the ADCs. In our series, it was observed a reduction risk of death 60,3 % for the patients with HIV infection and NADCs against the ADCs. It has also increased the prevalence of secondary tumors.